Abstract:Metastasis is the leading cause of breast cancer (BC) death, and tumor cells must migrate and invade to metastasize. BC cells that express the actin regulatory protein MenaINV have an enhanced ability to migrate and intravasate within the primary tumor, and extravasate at secondary sites. Though chemotherapy improves patient survival, treatment with paclitaxel, a chemotherapy used for BC, leads to upregulation of MenaINV and an increase in metastasis in mice. MenaINV expression can be induced in BC cells through Notch1 signaling with macrophages, which are often recruited to tumors in response to chemotherapy. MenaINV-expressing cells are also resistant to paclitaxel, begging the question of whether paclitaxel increases MenaINV by de novo induction or by selectively killing non-MenaINV-expressing cells. We hypothesized that paclitaxel causes de novo MenaINV induction by increasing macrophage-tumor cell Notch signaling. Understanding this pro-metastatic effect of chemotherapy is crucial to refining treatment strategies. MMTV-PyMT mice bearing spontaneous mammary tumors were used as a model of BC. Mice were treated with paclitaxel or vehicle every 5 days for a total of 3 treatments. To study the role of macrophages in the paclitaxel-mediated MenaINV increase, in addition to paclitaxel, one cohort of mice was co-administered the macrophage-depleting agent clodronate or vehicle. To study the role of Notch signaling, a second cohort of mice was co-administered the Notch inhibitor DAPT or vehicle. Immunofluorescence staining was used to evaluate tumors for: %MenaINV+ area, proportion of apoptotic cells, macrophage density, and macrophage expression of Notch ligands Jag1 and Jag2. Paclitaxel-treated tumors expressed significantly more MenaINV even when tumor cell death did not increase, indicating that chemotherapy increases MenaINV expression by induction. Both macrophages and Notch signaling were needed for this effect to occur. Interestingly, paclitaxel did not increase macrophage infiltration or macrophage expression of Notch ligands, suggesting that paclitaxel may increase MenaINV by acting on tumor cells to promote Notch signaling. Paclitaxel causes de novo MenaINV induction that is macrophage- and Notch-dependent. Studies aiming to further elucidate the mechanism behind paclitaxel-mediated MenaINV induction are ongoing. These results lay the groundwork for novel microenvironment-based therapies to alleviate the pro-metastatic effects of chemotherapy in BC. Citation Format: Madeline Friedman-DeLuca, George S. Karagiannis, Camille L. Duran, Luis Rivera Sanchez, Prachiben P. Patel, Suryansh Shukla, Nicole D. Barth, Ved P. Sharma, Michael Papanicolaou, John S. Condeelis, Maja H. Oktay, David Entenberg. Chemotherapy causes de novo induction of invasive breast cancer cells [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer; 2024 Nov 17-20; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2024;84(22_Suppl) nr C037.

Chemotherapy Enhances Tumor Vascularization Via Notch Signaling-Mediated Formation of Tumor-Derived Endothelium in Breast Cancer

Effect of transcatheter arterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor in cervical squamous cell carcinoma

Synergistic Anti-Tumor Effects Of Danshen Injections In Combination With Chemotherapy And Antiangiogenic Therapy Via Alleviating Tumor Stroma Fibrosis State

Antineoplastic Agents in Chemotherapy Facilitating Tumor Growth and Angiogenesis in the Interval Administrations.

Synergistic Effects And Mechanism Of Danshen Injection In Combination With Chemotherapy And Antiangiogenic Therapy For Colon Cancer

The Interaction of the Senescent and Adjacent Breast Cancer Cells Promotes the Metastasis of Heterogeneous Breast Cancer Cells through Notch Signaling

Chemotherapy-Induced Upregulation of Small Extracellular Vesicle-Associated PTX3 Accelerates Breast Cancer Metastasis

Specific Chemotherapeutic Agents Induce Metastatic Behaviour Through Stromal‐ and Tumour‐derived Cytokine and Angiogenic Factor Signalling

Chemotherapy-driven Increases in the CDKN1A/PTN/PTPRZ1 Axis Promote Chemoresistance by Activating the NF-κB Pathway in Breast Cancer Cells.

Chemotherapy May Facilitate Colorectal Cancer Metastasis Through Vessel Formation by Upregulating G-CSF

Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies

Tumor necrosis factor receptor 2 promotes endothelial cell-mediated suppression of CD8+ T cells through tuning glycolysis in chemoresistance of breast cancer

Abstract C037: Chemotherapy causes de novo induction of invasive breast cancer cells

Targeting DKK1 enhances the antitumor activity of paclitaxel and alleviates chemotherapy-induced peripheral neuropathy in breast cancer

Tumor-Derived Extracellular Vesicles Enable Tumor Tropism Chemo-Genetherapy for Local Immune Activation in Triple-Negative Breast Cancer

Fibroblast CEBPD/SDF4 Axis in Response to Chemotherapy-Induced Angiogenesis Through CXCR4

Tumor Priming Using Metronomic Chemotherapy with Neovasculature-Targeted, Nanoparticulate Paclitaxel

Breast Cancer Cells-Derived Von Willebrand Factor Promotes VEGF-A-related Angiogenesis Through PI3K/Akt-miR-205-5p Signaling Pathway

Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism

Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells.

Adrenergic signaling promotes angiogenesis through endothelial cell-tumor cell crosstalk.